Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Accelrys aquires Ireland-based Qumas, a provider of cloud-based and on-premises enterprise compliance software.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Roche announces changes to its board of directors scheduled for March 4, 2014.

FDA has issued a proposed rule to require manufacturers of antibacterial hand soaps and body washes to demonstrate that their products are safe for long-term daily use and more effective than plain soap and water.

Agency issues precautionary recall due to manufacturing fault.

Agency issues precautionary recall due to manufacturing fault.

Charles River Laboratories makes organizational changes to improve the company's productivity initiatives.

Moberg Pharma will acquire three OTC brands from Bayer HealthCare.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Phillips-Medisize announces the expansion to its Kontiolahti, Finland site.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

The University of Missouri's Department of Biochemistry and ABC Laboratories announce industry internship program.

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Harlan announces Hiroharu Okochi as president of Harlan Japan.

Johnson&Johnson will open a network of partnering offices across the UK.

AstraZeneca will receive $76 million in damages from Apotex Corp., Apotex, and Torpharm.

Shire's United States subsidiary enters supply agreement for Adderall XR.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

OGD is under pressure to improve review operations.

ScinoPharm completes new API manufacturing plant in Changshu, China.

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.